CN106176873B - Capsella bursa-pastoris total alkaloid extract and preparation method and application thereof - Google Patents
Capsella bursa-pastoris total alkaloid extract and preparation method and application thereof Download PDFInfo
- Publication number
- CN106176873B CN106176873B CN201610650471.6A CN201610650471A CN106176873B CN 106176873 B CN106176873 B CN 106176873B CN 201610650471 A CN201610650471 A CN 201610650471A CN 106176873 B CN106176873 B CN 106176873B
- Authority
- CN
- China
- Prior art keywords
- extract
- shepherd
- total alkaloid
- purse
- concentrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 88
- 235000011305 Capsella bursa pastoris Nutrition 0.000 title claims abstract description 46
- 240000008867 Capsella bursa-pastoris Species 0.000 title claims abstract description 46
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 46
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000000605 extraction Methods 0.000 title claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000706 filtrate Substances 0.000 claims abstract description 24
- 238000010828 elution Methods 0.000 claims abstract description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000001914 filtration Methods 0.000 claims abstract description 15
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003208 petroleum Substances 0.000 claims abstract description 14
- 238000010992 reflux Methods 0.000 claims abstract description 13
- 238000004440 column chromatography Methods 0.000 claims abstract description 11
- 239000006185 dispersion Substances 0.000 claims abstract description 9
- 239000000499 gel Substances 0.000 claims abstract description 9
- 238000010298 pulverizing process Methods 0.000 claims abstract description 9
- 239000011347 resin Substances 0.000 claims abstract description 9
- 229920005989 resin Polymers 0.000 claims abstract description 9
- 238000001179 sorption measurement Methods 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 9
- 239000002026 chloroform extract Substances 0.000 claims abstract description 8
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 238000011068 loading method Methods 0.000 claims abstract description 4
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 238000002156 mixing Methods 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 235000013305 food Nutrition 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 229940040461 lipase Drugs 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a preparation method of a shepherd's purse total alkaloid extract, which comprises the following steps: (1) pulverizing aerial parts of dried herba Capsellae, extracting with ethanol under reflux, collecting extractive solution, and concentrating to obtain extract; (2) adding HCl into the extract, stirring to obtain uniform dispersion liquid, and filtering to obtain filtrate; (3) adjusting the pH of the filtrate to be 8-10, extracting with chloroform, mixing the extracts, and concentrating to obtain chloroform extract; (4) subjecting the chloroform extract to silica gel column chromatography, and gradient eluting with petroleum ether-ethyl acetate mixture at volume ratio of 10:1 → 6:1 → 4: 1; (5) concentrating petroleum ether-ethyl acetate elution fraction at a volume ratio of 6:1, loading on Sephadex LH-20 gel adsorption resin column chromatography, eluting with methanol, and collecting elution fraction to obtain herba Capsellae total alkaloid extract. The extract has good effects of protecting liver and reducing blood fat, and the preparation method is simple.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine extracts, and particularly relates to a shepherd's purse total alkaloid extract and a preparation method and application thereof.
Background
Hepatitis b is a well-known infectious disease that presents a significant health hazard to humans. Hepatitis b is an infectious disease caused by Hepatitis B Virus (HBV), mainly as a hepatitis virus and eventually leading to multiple organ damage, and even some patients may turn to cirrhosis or liver cancer. At present, China is a high-development country of hepatitis B virus carriers, and according to statistics, the number of asymptomatic hepatitis B virus carriers in China is 1.3 hundred million, and the number of hepatitis B patients is 3000 ten thousand. Approximately 23.7 million people die each year from hepatitis b-related diseases, of which 15.6 die from liver cancer. Therefore, the preparation of a novel hepatitis B treatment medicament with remarkable curative effect and small toxic and side effects as soon as possible is an important task to be solved urgently by the medical scientists in China at present.
Meanwhile, with the improvement of living standard of people, the eating quality and habits of many people are changed, the number of people suffering from hyperlipidemia is increased year by year, hyperlipidemia becomes a global disease, and the disease trend is more and more younger, so that the prospect is worried. In addition, hyperlipidemia can cause complications such as coronary heart disease and atherosclerosis, which have serious threats to the physical and mental health of patients. Therefore, the research and development of the novel hypolipidemic drug have great social and economic benefits.
At present, the drugs related to the treatment of hepatitis B and hyperlipidemia in the market are mainly chemical synthetic drugs. It is known that the long-term administration of these chemicals will cause great harm to human body. It is appreciated that natural Chinese herbs have unique advantages in this respect. The shepherd's purse, a wild vegetable in folk, is very rich in nutrient substances and is deeply favored by people. According to the principle of homology of medicine and food, the capsella bursa-pastoris has the advantages of greenness, naturalness, small toxic and side effects, safety, reliability and the like in the aspect of medicine development. Modern pharmacological research shows that the shepherd's purse has the effects of resisting aging, inflammation and cancer, reducing blood pressure and the like. Researches also find that the shepherd's purse mainly contains chemical components such as flavonoids, organic acids, alkaloids and the like. At present, people do not deeply research the chemical components of the shepherd's purse, and particularly, other aspects of liver protection and blood fat reduction are not reported. Therefore, the shepherd's purse has a great research space in the aspect of drug development, the effective components of the shepherd's purse need to be further excavated, the relation between the pharmacological activity and the effective components is determined, and an important theoretical basis is laid for the human beings to find new drugs with liver protection activity and blood fat reduction from natural plants.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a shepherd's purse total alkaloid extract which has good liver protection and blood fat reduction effects.
The invention provides a preparation method of a shepherd's purse total alkaloid extract, which comprises the following steps:
(1) pulverizing aerial parts of dried herba Capsellae, extracting with ethanol under reflux, collecting extractive solution, and concentrating under reduced pressure at low temperature to obtain extract;
(2) adding HCl into the extract obtained in the step (1), stirring to obtain uniform dispersion liquid, standing, and filtering to obtain filtrate;
(3) adjusting the pH of the filtrate obtained in the step (2) to be 8-10, extracting with chloroform until no alkaloid reaction exists, combining the extract solutions, and concentrating to obtain a chloroform extract;
(4) performing silica gel column chromatography on the chloroform extract obtained in the step (3), and performing gradient elution by using petroleum ether-ethyl acetate mixed liquor with the volume ratio of 10:1 → 6:1 → 4:1 in sequence to obtain elution parts;
(5) concentrating the fraction eluted with petroleum ether-ethyl acetate with the volume ratio of 6:1 obtained in the step (4), loading on Sephadex LH-20 gel adsorption resin column chromatography, eluting with methanol with the mass fraction of 85-95%, and collecting the eluted fraction to obtain the capsella bursa-pastoris total alkaloid extract.
Preferably, the ethanol reflux extraction in the step (1) is heating reflux extraction for 2 to 3 times with ethanol with the mass percent of 80 to 95 percent, and each time lasts for 1.5 to 2.5 hours.
Preferably, the volume ratio of the extract to HCl in the step (2) is 1: 1; the mass percent of HCl is 1.0-2.0%.
Preferably, the standing time in the step (2) is 24 to 30 hours.
Preferably, the step (5) further comprises concentrating and drying under reduced pressure after collecting the eluted fraction.
The invention also provides the shepherd's purse total alkaloid extract prepared by the method.
The invention also provides application of the shepherd's purse total alkaloid extract in preparing liver-protecting medicines or foods.
The preparation method comprises the following steps.
In the preparation of food, the shepherd's purse total alkaloid extract is added into food raw materials and prepared according to a conventional method.
The invention also provides application of the shepherd's purse total alkaloid extract in preparation of blood fat reducing medicines or foods.
The invention also provides a medicament, the effective component of which is the shepherd's purse total alkaloid extract of claim 6.
Preferably, the composition also comprises medically acceptable auxiliary materials.
The invention has the advantages that the shepherd's purse with dual purposes of medicine and food' is selected as a raw material source, the preparation method is simple and convenient, the raw materials are saved, the preparation process is easy to control, the yield is high, the production process is green and environment-friendly, can be circularly carried out, is suitable for batch production, and has good effects of protecting liver and reducing blood fat.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1 is a flow chart of the preparation method of the shepherd's purse total alkaloid extract of the present invention.
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples are commercially available unless otherwise specified.
The preparation method of the shepherd's purse total alkaloid extract comprises the following steps:
(1) taking dried herba Capsellae aerial part as raw material, pulverizing to 0.5-1.0 cm, adding 80-95% ethanol by mass, and extracting under heating and refluxing for 2-3 times, each for 1.5-2.5 hr. Filtering, collecting filtrate, and concentrating under reduced pressure at low temperature (40-55 deg.C) to obtain extract;
(2) adding 1.0-2.0% of HCl (extract: HCl =1:1, V/V) in percentage by mass into the extract obtained in the step (1), stirring to obtain uniform dispersion, standing for 24-30 hours, and filtering to obtain filtrate for later use; namely, an acid-soluble alkali-precipitation method is adopted for extraction; the hydrochloric acid can completely dissolve the capsella bursa-pastoris total alkali;
(3) adjusting the pH of the filtrate obtained in the step (2) to 8-10 by using ammonia water, extracting by using chloroform until no alkaloid reaction exists, combining the extract liquor and concentrating to obtain a chloroform extract;
(4) performing silica gel (100-200 mesh) column chromatography on the chloroform extract obtained in the step (3), sequentially performing gradient elution by using petroleum ether-ethyl acetate mixed liquor with the volume ratio of 10:1 → 6:1 → 4:1 to obtain elution parts, and concentrating the elution parts into thick paste for later use;
(5) and (3) loading the petroleum ether-ethyl acetate elution fraction obtained in the step (4) in a volume ratio of 6:1 onto SephadexLH-20 gel adsorption resin column chromatography, eluting with 85-95% by mass of methanol, combining the obtained elution fractions, and concentrating and drying under reduced pressure to obtain the capsella bursa-pastoris total alkaloid extract with the extraction rate of 0.5-1%.
Tests prove that the shepherd's purse total alkaloid extract prepared by the method has the effects of protecting the liver and reducing the lipid activity.
Example 1
Pulverizing the above-ground part of dried herba Capsellae to 0.6 cm, extracting with 85% ethanol under reflux for 2 times (each for 1.5 hr), filtering, collecting filtrate, and concentrating under reduced pressure at 50 deg.C to obtain soft extract. Then adding 1.2% of HCl (extract: HCl =1:1, V/V) in percentage by mass, stirring to obtain a uniform dispersion, standing for 26 hours, and filtering to obtain a filtrate; adjusting pH of the filtrate to =8 with ammonia water, extracting with chloroform until no alkaloid reaction occurs to obtain extract, mixing the extracts, concentrating, and drying to obtain extract. Subjecting the extract to silica gel (100-; separating petroleum ether-ethyl acetate elution fraction with volume ratio of 6:1 on Sephadex LH-20 gel adsorption resin column chromatography, eluting with 85% methanol by mass, mixing the obtained elution fractions, and finally concentrating and drying under reduced pressure to obtain the shepherd's purse total alkaloid extract with extraction rate of 0.9%.
Example 2
Pulverizing the above-ground part of dried herba Capsellae to 0.8 cm, extracting with 90% ethanol under reflux for 2 times (2.0 hr each time), filtering, collecting filtrate, and concentrating under reduced pressure at 40 deg.C to obtain soft extract. Then adding 1.6% of HCl (extract: HCl =1:1, V/V) in percentage by mass, stirring to obtain a uniform dispersion, standing for 28 hours, and filtering to obtain a filtrate; adjusting pH of the filtrate to = 9 with ammonia water, extracting with chloroform until no alkaloid reaction occurs to obtain extract, mixing the extracts, concentrating, and drying to obtain extract. Subjecting the extract to silica gel (100-200 mesh) column chromatography, gradient eluting with petroleum ether-ethyl acetate mixed solution at volume ratio of 10:1 → 6:1 → 4:1 in sequence to obtain each eluting part, concentrating into soft extract, subjecting the petroleum ether-ethyl acetate eluting fraction at volume ratio of 6:1 to Sephadex LH-20 gel adsorption resin column chromatography, eluting with 90% methanol by mass percent, mixing the obtained eluting fractions, and concentrating and drying under reduced pressure to obtain herba Capsellae total alkaloid extract with extraction rate of 1%.
Example 3
Pulverizing the above-ground part of dried herba Capsellae to 1.0 cm, extracting with 95% ethanol under reflux for 3 times (2.5 hr each time), filtering, collecting filtrate, and concentrating under reduced pressure at 55 deg.C to obtain soft extract. Then adding 1.8% of HCl (extract: HCl =1:1, V/V) in percentage by mass, stirring to obtain a uniform dispersion, standing for 30 hours, and filtering to obtain a filtrate; adjusting pH of the filtrate to = 10 with ammonia water, performing alkaloid-free reaction with chloroform to obtain extract, mixing the extracts, concentrating, and drying to obtain extract. Subjecting the extract to silica gel (100-; separating petroleum ether-ethyl acetate eluate at volume ratio of 6:1 with Sephadex LH-20 gel adsorption resin column chromatography, eluting with 95% methanol by mass, mixing the eluates, concentrating under reduced pressure, and drying to obtain herba Capsellae total alkaloid extract with extraction rate of 0.6%.
Example 4
Pulverizing the above-ground part of dried herba Capsellae to 0.5 cm, extracting with 80% ethanol under reflux for 3 times (2.5 hr each time), filtering, collecting filtrate, and concentrating under reduced pressure at 45 deg.C to obtain soft extract. Then adding 1.0% of HCl (extract: HCl =1:1, V/V) in percentage by mass, stirring to obtain uniform dispersion, standing for 24 hours, and filtering to obtain filtrate; adjusting pH of the filtrate to = 10 with ammonia water, performing alkaloid-free reaction with chloroform to obtain extract, mixing the extracts, concentrating, and drying to obtain extract. Subjecting the extract to silica gel (100-; separating petroleum ether-ethyl acetate elution fraction with volume ratio of 6:1 on Sephadex LH-20 gel adsorption resin column chromatography, eluting with 90% methanol by mass, mixing the obtained elution fractions, and finally concentrating and drying under reduced pressure to obtain the shepherd's purse total alkaloid extract with extraction rate of 0.5%.
Example 5
Pulverizing the above-ground part of dried herba Capsellae to 0.8 cm, extracting with 85% ethanol under reflux for 3 times (2.0 hr each time), filtering, collecting filtrate, and concentrating under reduced pressure at 55 deg.C to obtain soft extract. Then adding 2.0% of HCl (extract: HCl =1:1, V/V) in percentage by mass, stirring to obtain uniform dispersion, standing for 28 hours, and filtering to obtain filtrate; adjusting pH of the filtrate to = 9 with ammonia water, performing alkaloid-free reaction with chloroform to obtain extractive solution, mixing the extractive solutions, concentrating, and drying to obtain extract. Subjecting the extract to silica gel (100-; separating petroleum ether-ethyl acetate elution fraction with a volume ratio of 6:1 on Sephadex LH-20 gel adsorption resin column chromatography, eluting with 85% methanol by mass, mixing the obtained elution fractions, and finally concentrating and drying under reduced pressure to obtain the shepherd's purse total alkaloid extract with an extraction rate of 0.85% -1%.
Example 6 application experiment of the Capsella bursa-pastoris total alkaloid extract of the invention
(ii) hepatoprotective Activity
(1) The influence of the shepherd's purse total alkaloid extract on the survival rate of HL-7702 cells is observed by an MTT method. The MTT method is called 3- (4, 5-dimethylthiazolidil-2-yl) -2,5-diphenyltetrazolium bromide, and is named as 3- (4, 5-dimethylthiazole-2) -2,5-diphenyl tetrazolium bromide, which is called as tetrazolium salt for short, and thiazole blue for short. MTT colorimetric assay is a common method for detecting cell growth and survival rate. It means that the amount of MTT crystal formed is directly proportional to the number of cells and metabolic activity within a certain range of cell number. Dimethyl sulfoxide (DMSO) was able to solubilize formazan crystals in cells, and the absorbance value A (OD value) was measured at 570nm by an enzyme-linked immunosorbent assay. And (4) judging the number of living cells according to the measured absorbance value, wherein the larger the OD value is, the stronger the cell activity is. Therefore, the change of the light absorption value of the tumor cells after the antitumor drug is added is measured, and the inhibition rate of the drug on the cells is calculated, so that the sensitivity degree of the tumor cells to the drug is presumed to know the action degree of the drug.
(2) Placing HL-7702 cells at 37 deg.C and containing 5% CO2The culture medium is DMEM (10% fetal bovine serum, 100U/mL penicillin and 100)μg/mL streptomycin, pH 7.2-7.4).
(3) Grouping experiments:
normal group: HL-7702 cells;
control group: D-GalN (D-galactosamine);
control group: a bicyclol;
sample group: the shepherd's purse total alkaloid extract prepared in embodiment 3 of the invention;
(3) dispersing the cells in a medium to a density of 1X 105Single cell per mLThe suspension was added to a 96-well plate at 0.1 mL per well. And changing a culture medium containing the test drug after 24 h of culture, wherein the concentration of the test drug in the culture medium is 50 mug/ml, and adding D-galactosamine (the final concentration is 50 mmol/L) for continuous culture 1 h after administration. After 24 hours after the administration, the medium containing MTT (0.5 mg/mL) in the serum-free medium was replaced, and after 4 hours of incubation, the medium was aspirated, dissolved by adding DMSO (150. mu.L/air) and the absorbance of each well was measured at 490 nm with shaking. Inhibition (%) = [ (OD)(sample set)- OD(control group))/(OD(Normal group)-OD(control group))]X 100. The results of the experiment are shown in Table 1.
TABLE 1 protective action of Capsella bursa-pastoris Total alkaloid extract on liver cell damage
Note: the sample group is shepherd's purse total alkaloid extract; the control group was bicyclic alcohol.ap<0.05。
The experimental results (table 1) show that the shepherd's purse total alkaloid extract has obvious liver protection effect, and the survival rate of the extract on injured liver cells is obviously higher than that of a positive control medicament bicyclol from the experimental data. Therefore, the total alkaloid extract has important guiding significance for developing a medicament with liver protection effect from ' dual-purpose medicine and food ' shepherd ' herb.
(II) lipid-lowering Activity
(1) Dissolving calcium chloride 0.294g in 0.2mol/L trihydroxymethyl aminomethane solution 40mL, adjusting pH to 8.1 with 1mol/L hydrochloric acid solution, and diluting with water to 100mL to obtain trihydroxymethyl aminomethane buffer solution (pH 8.1).
(2) Preparing the shepherd's purse total alkaloid extract into sample solutions with different concentrations by using a trihydroxymethyl aminomethane buffer solution; preparing 10mg of porcine pancreatic lipase into 1mg/mL enzyme solution by using a trihydroxymethyl aminomethane buffer solution; meanwhile, preparing 4-methylumbelliferone oleate into a 0.1mmol/L substrate solution by using a tris buffer solution; a 0.1mmol/L solution of sodium citrate was prepared using tris buffer and adjusted to pH =4.2 with HCl for use.
(3) Adding 30 mu L of the sample liquid obtained in the step (2) into 30 mu L of the enzyme solution, and fully and uniformly mixing; a further 60. mu.L of substrate solution was added, incubated at 25 ℃ for 20 minutes and the reaction was stopped with 110. mu.L of sodium citrate solution. The final concentrations of the samples to be tested are 600, 300, 150, 75, 37.5 and 18.8 mu g/mL respectively.
(4) The method comprises the steps of selecting a sample solution, an enzyme solution and a substrate solution to be mixed as a sample group, selecting the sample solution and the substrate solution to be mixed as a background group, selecting the enzyme solution and the substrate solution to be mixed as a control group, and selecting the substrate solution as a blank control group. The absorbance was measured at 320nm excitation light and 450nm emission light, respectively. Lipase inhibition of the compounds was then calculated according to the formula. The results are shown in Table 2. The lipase inhibition rate calculation formula is as follows: lipase inhibition% =1- (sample group-background group)/(control group-blank control group) × 100%. See table 2 for results.
TABLE 2 results of lipid-lowering Activity of Capsella bursa-pastoris Total alkaloid extract
The experimental data show that the shepherd's purse total alkaloid extract has an obvious inhibition effect on the porcine pancreatic lipase, and the lipase inhibition rate is as high as 90.24%. Therefore, the capsella bursa-pastoris total alkaloid extract has important significance for developing a medicament with lipid-lowering activity from 'medicinal and edible' capsella bursa-pastoris.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (6)
1. A preparation method of a shepherd's purse total alkaloid extract is characterized in that: the method comprises the following steps:
(1) pulverizing aerial parts of dried herba Capsellae, extracting with ethanol under reflux, collecting extractive solution, and concentrating under reduced pressure at low temperature to obtain extract;
(2) adding HCl into the extract obtained in the step (1), stirring to obtain uniform dispersion liquid, standing, and filtering to obtain filtrate;
(3) adjusting the pH of the filtrate obtained in the step (2) to be 8-10, extracting with chloroform until no alkaloid reaction exists, combining the extract solutions, and concentrating to obtain a chloroform extract;
(4) performing silica gel column chromatography on the chloroform extract obtained in the step (3), and performing gradient elution by using petroleum ether-ethyl acetate mixed liquor with the volume ratio of 10:1 → 6:1 → 4:1 in sequence to obtain elution parts;
(5) concentrating the petroleum ether-ethyl acetate elution fraction obtained in the step (4) in a volume ratio of 6:1, loading on Sephadex LH-20 gel adsorption resin column chromatography, eluting with 85-95% methanol by mass fraction, and collecting the elution fraction to obtain a shepherd's purse total alkaloid extract;
the ethanol reflux extraction in the step (1) is to heat and reflux extract for 2 to 3 times by using 80 to 95 mass percent of ethanol, wherein each time lasts for 1.5 to 2.5 hours;
the volume ratio of the extract to HCl in the step (2) is 1: 1; the mass percent of the HCl is 1.0-2.0%, and the standing time is 24-30 hours;
in the step (5), after the elution fraction is collected, the method further comprises the step of concentrating under reduced pressure and drying.
2. The shepherd's purse total alkaloid extract prepared by the method of claim 1.
3. The use of the shepherd's purse total alkaloid extract of claim 2 in preparing liver-protecting medicaments.
4. The application of the shepherd's purse total alkaloid extract of claim 2 in preparing a medicament for reducing blood fat.
5. A medicament, characterized by: the effective component of the shepherd's purse total alkaloid extract is the shepherd's purse total alkaloid extract of claim 2.
6. The medicament of claim 5, wherein: also comprises medically acceptable auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610650471.6A CN106176873B (en) | 2016-08-10 | 2016-08-10 | Capsella bursa-pastoris total alkaloid extract and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610650471.6A CN106176873B (en) | 2016-08-10 | 2016-08-10 | Capsella bursa-pastoris total alkaloid extract and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106176873A CN106176873A (en) | 2016-12-07 |
| CN106176873B true CN106176873B (en) | 2020-04-21 |
Family
ID=57514724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610650471.6A Expired - Fee Related CN106176873B (en) | 2016-08-10 | 2016-08-10 | Capsella bursa-pastoris total alkaloid extract and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176873B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115226728B (en) * | 2022-04-29 | 2023-07-25 | 乐山师范学院 | Preparation method and application of radix seu herba Gei aleppici alkaloid extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1193019A (en) * | 1997-03-06 | 1998-09-16 | 承德医学院中药研究所 | Effective components of wild opium poppy and extracting process and product thereof |
| CN105111263A (en) * | 2015-08-31 | 2015-12-02 | 南阳师范学院 | Flavones separated and purified from shepherd's purse, and preparation method and application thereof |
-
2016
- 2016-08-10 CN CN201610650471.6A patent/CN106176873B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1193019A (en) * | 1997-03-06 | 1998-09-16 | 承德医学院中药研究所 | Effective components of wild opium poppy and extracting process and product thereof |
| CN105111263A (en) * | 2015-08-31 | 2015-12-02 | 南阳师范学院 | Flavones separated and purified from shepherd's purse, and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 大蓟中木脂素类化学成分研究;宁恺佳等;《南阳师范学院学报》;20160630;第15卷(第6期);第17-21页 * |
| 小蓟中黄酮类化学成分的研究;马勤阁等;《中国中药杂志》;20160331;第41卷(第5期);第868-873页 * |
| 荠菜中总生物碱提取工艺研究;刘春风;《化学工业与工程》;20110531;第28卷(第3期);第41-42页第1.2节 * |
| 超声波强化提取荠菜中总生物碱的研究;潘明;《化学与生物工程》;20061231;第23卷(第11期);第33-35页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106176873A (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103027953B (en) | Extractive containing total meroterpenoid of psidium guajave dialdehyde, and preparation method and application thereof | |
| CN100575358C (en) | Flos Lonicerae extract, its preparation method and application | |
| AU2022352631B2 (en) | Azulene compound, and preparation method therefor and use thereof | |
| CN109846896B (en) | Application of hederagenin in preparation of medicine for resisting inflammatory injury of vascular endothelial cells | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN109674802A (en) | Steroid compound purposes in preparing anti-inflammatory drugs | |
| CN115154476A (en) | Cyclocarya paliurus extract and application thereof in resisting gout and reducing uric acid | |
| CN105920064A (en) | Natural active ingredient extracted and separated from leaves and stems of panax quinuefolium L and application of natural active ingredient | |
| Jin et al. | Study the mechanism of peimisine derivatives on NF‐κB inflammation pathway on mice with acute lung injury induced by lipopolysaccharide | |
| CN106176873B (en) | Capsella bursa-pastoris total alkaloid extract and preparation method and application thereof | |
| CN110016007B (en) | Cyclic diphenylheptanes, preparation method thereof, application thereof, medicament and dietary supplement | |
| CN116041307A (en) | Preparation method of 4, 9-dihydroxyl-alpha-lapachone from catalpa bungei | |
| CN103191143B (en) | New application of cardiac glycoside compound | |
| CN110522776B (en) | Preparation method and application of anti-tumor effective part in hibiscus syriacus | |
| CN104945460A (en) | Preparation method and applications of roxburic acid | |
| CN101396373A (en) | Cinobufacini extract and preparation method thereof | |
| CN111499605B (en) | Isopentene chromone compound and preparation method and application thereof | |
| CN108948040B (en) | Gilmaxane type sesquiterpene compound extracted from herba Centellae and application thereof | |
| CN111892634A (en) | Glucoside compound from raw materials, extraction method and application thereof | |
| CN102250197A (en) | Preparation method and application of total steroidal saponin extracts of dwarf lilyturf roots | |
| CN107722087B (en) | Gynostemma pentaphylla flavonoid compound, preparation method thereof and application thereof in antitumor drugs | |
| CN107513092B (en) | Malonyl ginsenoside Rb1Preparation method and medical application thereof | |
| CN102028698B (en) | Medicine for treating colon cancer and preparation method thereof | |
| CN106349021B (en) | Compound in reineckea carnea and preparation and application thereof | |
| CN111084791A (en) | Application of polyrhachis vicina Roger extract in preparation of medicines for preventing and treating breast cancer and related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200421 Termination date: 20200810 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |